SCHEDULE 13G

0001193125-05-018157.txt : 20120705 0001193125-05-018157.hdr.sgml : 20120704 20050203101231 ACCESSION NUMBER: 0001193125-05-018157 CONFORMED SUBMISSION TYPE: SC 13G PUBLIC DOCUMENT COUNT: 1 FILED AS OF DATE: 20050203 DATE AS OF CHANGE: 20050203 GROUP MEMBERS: PHARMACEUTICAL PRODUCT DEVELOPMENT, INC. ("PPD") SUBJECT COMPANY: COMPANY DATA: COMPANY CONFORMED NAME: CHEMOKINE THERAPEUTICS CORP CENTRAL INDEX KEY: 0001092959 STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836] IRS NUMBER: 330921251 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: SC 13G SEC ACT: 1934 Act SEC FILE NUMBER: 005-80288 FILM NUMBER: 05571676 BUSINESS ADDRESS: STREET 1: 2386 EAST MALL STREET., SUITE 208 STREET 2: SUITE 208 CITY: VANCOUVER STATE: A1 ZIP: V6T 1Z3 BUSINESS PHONE: 604-8220301 MAIL ADDRESS: STREET 1: 2386 EAST MALL STREET., SUITE 208 CITY: VANCOUVER STATE: A1 ZIP: V6T 1Z3 FORMER COMPANY: FORMER CONFORMED NAME: PTM MOLECULAR BIOSYSTEMS INC DATE OF NAME CHANGE: 20000204 FILED BY: COMPANY DATA: COMPANY CONFORMED NAME: PHARMACEUTICAL PRODUCT DEVELOPMENT INC CENTRAL INDEX KEY: 0001003124 STANDARD INDUSTRIAL CLASSIFICATION: SERVICES-COMMERCIAL PHYSICAL & BIOLOGICAL RESEARCH [8731] IRS NUMBER: 561640186 STATE OF INCORPORATION: NC FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: SC 13G BUSINESS ADDRESS: STREET 1: 3151 SOUTH 17TH ST CITY: WILMINGTON STATE: NC ZIP: 28412 BUSINESS PHONE: 9102510081 MAIL ADDRESS: STREET 1: 3151 SOUTH 17TH ST CITY: WILMINGTON STATE: NC ZIP: 28412 SC 13G 1 dsc13g.htm SCHEDULE 13G SCHEDULE 13G

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

SCHEDULE 13G

UNDER THE SECURITIES EXCHANGE ACT OF 1934

(Amendment No. )*

CHEMOKINE THERAPEUTICS CORP.

(Name of Issuer)

Common Stock

(Title of Class of Securities)

16383P107

(CUSIP Number)

December 31, 2004

(Date of Event Which Requires Filing of this Statement)

Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

¨ Rule 13d-1(b)

¨ Rule 13d-1(c)

x Rule 13d-1(d)

*	The remainder of this cover page shall be filled out for a reporting person’s initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter disclosures provided in a prior cover page.

The information required on the remainder of this cover page shall not be deemed to be “filed” for the purpose of Section 18 of the Securities Exchange Act of 1934 (“Act”) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

CUSIP Number 16383P107

Page 2 of 5


1.		Name of Reporting Person S.S. or I.R.S. Identification No. of Reporting Person Pharmaceutical Product Development, Inc.
2.		Check the Appropriate Box if a Member of a Group (See Instructions) (a) ¨ (b) ¨
3.		SEC Use Only
4.		Citizenship or Place of Organization North Carolina

Number of

Beneficially

Owned By

Each

Reporting

Person

With:

5. Sole Voting Power

2,500,000

6. Shared Voting Power

7. Sole Dispositive Power

2,500,000

8. Shared Dispositive Power


9.	Aggregate Amount Beneficially Owned by Each Reporting Person 2,500,000
10.	Check if the Aggregate Amount in Row (9) Excludes Certain Shares (See Instructions)	¨
11.	Percent of Class Represented by Amount in Row (9) 7.9%
12.	Type of Reporting Person (See Instructions) CO

CUSIP Number 16383P107

Page 3 of 5

Item 1

(a).

Name of Issuer

Chemokine Therapeutics Corp. (the “Issuer”)

Item 1

(b).

Address of the Issuer’s Principal Executive Office

2386 East Mall Street, Suite 208

University of British Columbia

Vancouver, British Columbia V6T1Z3

Item 2

(a).

Name of Person Filing

Pharmaceutical Product Development, Inc. (“PPD”)

Item 2

(b).

Address of the Filing Person’s Principal Business Office:

The address of the principal business office of PPD is:

3151 South 17^th Street

Wilmington, North Carolina 28412

Item 2

(c).

Place of Organization

North Carolina

Item 2

(d).

Title of Class of Securities

Common Stock

Item 2

(e).

Cusip Number

16383P107

Item 3.

Filing Pursuant to Rules 13d-1(b) or 13d-2(b)

Not Applicable

CUSIP Number 16383P107

Page 4 of 5



Item 4.	Ownership

	(a)	Amount Beneficially Owned: See Row (9) on Page 2. Reported share ownership on this Schedule 13G represents amounts beneficially owned by PPD as of the date of the event requiring the filing of this report. These shares include (i) 2,000,000 shares of the Issuer’s common stock issuable upon conversion of 2,000,000 shares of the Issuer’s Series A preferred stock held by PPD, and (ii) 500,000 shares of the Issuer’s common stock issuable upon exercise of share purchase warrants held by PPD.

	(b)	Percent of Class: See Row (11) on Page 2.

	(c)	Sole Power vs. Shared Power to Vote and Dispose of Shares: See Rows (5)-(8) on Page 2.

Item 5.	Ownership of Five Percent or Less of a Class Not Applicable

Item 6.	Ownership of More than Five Percent on Behalf of Another Person Not Applicable

Item 7.	Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on By the Parent Holding Company Not Applicable

Item 8.	Identification and Classification of Members of the Group Not Applicable

Item 9.	Notice of Dissolution of Group Not Applicable

CUSIP Number 16383P107

Page 5 of 5

Item 10.

Certification

After reasonable inquiry and to the best of its knowledge and belief, the undersigned certifies that the information set forth in this statement is true, complete and correct.

Dated:

February 1, 2005


Pharmaceutical Product Development, Inc.

By:	/s/ B. Judd Hartman	(SEAL)
Name:	B. Judd Hartman
Title:	General Counsel